Medpace Stock Falls On Q4 Earnings: The Details

Comments
Loading...
Zinger Key Points

Medpace Holdings Inc MEDP reported fourth-quarter financial results after the market close on Monday. Here’s a rundown of the report.

  • Q4 Revenue: $536.6 million, versus estimates of $534.78 million
  • Q4 EPS: $3.67, versus estimates of $2.96

Total revenue was up 7.7% on a year-over-year basis. New business awards totaled $529.7 million in the quarter, down 13.8% year-over-year. The company ended the period with a backlog of approximately $2.9 billion, up 3.2% year-over-year.

Medpace generated $190.7 million in cash flow from operations during the quarter. The company had cash and cash equivalents of $669.4 million as of Dec. 31.

Medpace said it repurchased $174.2 million of its common stock during the quarter. The company had $134.6 million remaining under its buyback at quarter’s end. Additionally, Medpace’s board approved an increase of $600 million to the company’s buyback program on Feb. 6.

Check This Out: Lattice Semiconductor Shares Jump After Mixed Q4 Results, Strong Q1 Guidance

Outlook: Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. The company sees full-year earnings in the range of $11.93 per share to $12.69 per share.

Medpace executives will further discuss the quarter on a call with investors and analysts at 9 a.m. ET Tuesday morning.

MEDP Price Action: At publication time Monday, Medpace shares were down 8.33% at $324.97 in after-hours trading, according to Benzinga Pro.

Photo: Shutterstock.

MEDP Logo
MEDPMedpace Holdings Inc
$305.282.54%

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score
Edge Rankings
Momentum
27.40
Growth
72.11
Quality
93.46
Value
5.84
Price Trend
Short
Medium
Long
Got Questions? Ask
Which healthcare stocks may benefit from Medpace's performance?
How will Medpace's buyback program influence investor sentiment?
Is the clinical research sector facing opportunities with Medpace's growth?
What impact will Medpace's backlog have on future earnings?
Could medical technology firms see increased partnerships with Medpace?
How might pharmaceutical companies react to Medpace's earnings report?
What does Medpace's cash flow indicate for its operational stability?
Is there a trend in investments in clinical trial firms post-Medpace earnings?
Which biotech stocks could be affected by Medpace's forecasts?
How will market analysts view Medpace's future revenue guidance?
Market News and Data brought to you by Benzinga APIs
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise

Posted In: